Queljoe, Doddy de and Lorensia, Amelia and Widharta, Liana and Widjaja, Sugiarto (2013) COST-EFFECTIVENESS ANALYSIS OF PHARMACOTHERAPY FOR HEMATEMESIS-MELENA TREATMENT IN HOSPITALIZED PATIENT WITH HEPATIC CIRRHOSIS. The Indonesian Boimedical Journal, 5 (1). pp. 53-62. ISSN 2085-3297
Preview |
PDF
10_abstrak_2013.pdf Download (681kB) | Preview |
Preview |
PDF
10A.pdf Download (3MB) | Preview |
Abstract
BACKGROUND: Acute variceal haemorrhage is a complication of cirrhosis, which could have life threatening impact. It is a pharmacist duty to ensure therapeutic and pharmaceutical care which is not only safe and effective for patients but has also a cost-effective property which purpose is the improvement of patient’s quality of life. Therefore, pharmacoeconomic evaluation specifically CEA (cost-effectiveness analysis) which compare cost and consequences of therapy is needed. This study was aimed to evaluate therapeutic cost-effectiveness of hematemesis-melena treatment in hepatic cirrhosis patients. METHODS: A total of 42 patients receiving vitamin K-only parenterally and combination of vitamin K+transamin parenterally were studied retrospectively from patient’s medical record in 2 years, and analyzed with cost-effectiveness grid and ACER (average cost-effectiveness ratio) based on Child-Turcotte-Pugh Score. RESULTS: Cost-effectiveness grid showed dominant for vitamin K-only in patient with Child-Turcotte-Pugh Score A. ACER analysis showed lower score for vitamin K-only in all patient included Child-Turcotte Pugh Score classification. There were no significant difference for duration of cessation of bleeding treatment in patients with vitamin K-only compare to vitamin K+transamin in patients with Child-Turcotte Pugh Score A and B, while there was significant difference in patients with Child-Turcotte Pugh Score C. CONCLUSION: Vitamin K-only appear to be more cost-effective compare to vitamin K+transamin in all patients. The use of vitamin K-only has greater benefit than the combination of vitamin K with transamin in all patient and Child-Turcotte-Pugh score classification, and should be considered as a primary therapy. Thus, transamin addition as an alternative therapy for hepatic cirrhosis patient with hematemesis-melena should be reconsidered.
| Item Type: | Article |
|---|---|
| Uncontrolled Keywords: | CEA (Cost-Effectiveness Analysis), ACER (average cost-effectiveness ratio), hepatic cirrhosis, hematemesis-melena, vitamin K. |
| Subjects: | R Medicine > RM Therapeutics. Pharmacology R Medicine > RS Pharmacy and materia medica |
| Divisions: | Faculty of Pharmacy > Department of Pharmacy |
| Depositing User: | AMELIA LORENSIA, S.FARM., M.FARM-KLIN., APT. 208019 |
| Date Deposited: | 09 Apr 2015 08:38 |
| Last Modified: | 09 Apr 2015 08:38 |
| URI: | http://repository.ubaya.ac.id/id/eprint/23900 |
Actions (login required)
 |
View Item |
